- Types of Eczema
- Child Eczema
- Causes & Triggers
- Living with Eczema
- Eczema Products
- Get Involved
By Debbie Byrnes Itching for a Cure (IFAC). It’s a feel-good day surrounded by people who respect you for your perseverance. And it’s the only walk for eczema and helps raise money for research, support, and education. This year, IFAC will take place on Sunday, October 2, in Los Angeles. When I think of all […]
We asked, you answered. The verdict? People living with eczema want more information and more options. This past January, many of you responded to a 6-question online survey to evaluate patient satisfaction and the role of doctors in the treatment of the most serious form of eczema, atopic dermatitis (AD). We learned that the vast majority of […]
Vice President, Advocacy and Access. Tim will be responsible for development and implementation of key advocacy initiatives that will advance NEA’s mission to improve the quality of life for individuals with eczema through research, support, and education. Tim most recently served as President of Foretop, a consulting firm that provided advocacy and business planning services […]
June 9, 2016 – On Monday, June 6, 2016 the pharmaceutical companies Regeneron and Sanofi, reported positive results for the Phase 3 the clinical trial of the new biologic drug, dupilumab, when used in conjunction with a topical corticosteroid by adults to treat moderate-to-severe atopic dermatitis (AD).
November 17, 2016 – This year, more than 450 people joined NEA on two successful Itching for a Cure (IFAC) Walks in Chicago, IL and Los Angeles, CA. Together, we raised nearly $120,000 to improve the quality of life for individuals with eczema through research, support, and education.
May 22, 2015 – “Eczema keeps me from doing things that other people enjoy all the time, like going to the beach, riding my bike, going for a walk, and enjoying being outside,” says 13-year-old eczema patient, Isaiah Dixon. But that didn’t stop Isaiah from testifying in March at a Food and Drug Administration (FDA) hearing in Silver Spring, MD, on behalf of the National Eczema Association.
NEA formed a Scientific Advisory Committee Task Force to conduct a systematic review of topical corticosteroid withdrawal/topical steroid addiction in patients with atopic dermatitis and other dermatoses, and created a NEA education announcement on Topical Steroid Addiction/Withdrawal.
March 10, 2015 – On March 9, 2015, NEA CEO Julie Block, 13-year old eczema patient Isaiah, 17-year old eczema patient Gracie, and their parents were present at an important Food and Drug Administrative (FDA) hearing regarding the unmet medical need for atopic dermatitis therapies in pediatrics.
January 6, 2015 – For the first time, a team led by researchers at the Icahn School of Medicine at Mount Sinai has proven that atopic dermatitis, also known as eczema, is an immune-driven (autoimmune) disease.
December 16, 2014 – Archive of Hope for Eczema: New Treatment Developments is now available.